Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001564590-20-018497
Filing Date
2020-04-24
Accepted
2020-04-24 16:10:26
Documents
5
Effectiveness Date
2020-04-24

Document Format Files

Seq Description Document Type Size
1 DEFA14A ntla-defa14a_20200618.htm DEFA14A 29863
2 GRAPHIC gr2qyikd50cj000003.jpg GRAPHIC 26270
3 GRAPHIC gr2qyikd50cj000001.jpg GRAPHIC 52008
4 GRAPHIC gr2qyikd50cj000004.jpg GRAPHIC 13980
5 GRAPHIC gr2qyikd50cj000002.jpg GRAPHIC 73680
  Complete submission text file 0001564590-20-018497.txt   259945
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-37766 | Film No.: 20815047
SIC: 2835 In Vitro & In Vivo Diagnostic Substances